IAA (Insulin And Abatacept) is a randomised controlled trial testing whether the combination of two safe disease-modifying therapies called abatacept and nasal insulin slows down the immune attack on the insulin-producing (beta) cells of people with newly-diagnosed type 1 diabetes. Abatacept is a disease-modifying medication approved for treatment of rheumatoid arthritis in both adults and […]
If you were allocating money for health treatment and care, would it be different for children or young people compared to adults? We are looking to interview young people aged 15 years old. We are interested in your views on how decisions about funding medicines and health services should be made. This will assist policy […]
Regular exercise is a cornerstone for managing type 1 diabetes (T1D), but many people with T1D face obstacles that stop them meeting physical activity guidelines. However, athletes with T1D are highly proficient at managing their condition within the context of their sport. For this reason, their strategies may offer valuable lessons for managing blood glucose […]
Regular exercise is important for health and has additional health benefits for children with type 1 diabetes, including improvements in mental health and reduced cardiovascular disease risk factors. Despite the benefits of exercise, research shows that high school aged adolescents with type 1 diabetes may experience additional barriers to exercise, including fear of hypoglycaemia or […]
Harmful patterns of insulin resistance in the muscle and liver may be an explanation for increased cardiovascular disease in T1D. The INTIMET study is a detailed investigation of insulin resistance in T1D and will test if metformin can improve insulin action in muscle and the liver. Participants will be asked to take metformin (or placebo […]
Cell Care is partnering with The Children’s Hospital at Westmead, New South Wales, in a world–first study investigating the potential of cord blood to prevent or delay the onset of type 1 diabetes in children at high risk of developing the disease. The CORD study has been approved by the Sydney Children’s Hospitals Network Human […]
This clinical trial is investigating whether fenofibrate, a drug used to lower cholesterol, can slow or reverse eye damage in adults with type 1 diabetes. Fenofibrate has been shown to slow eye damage in type 2 diabetes, and researchers are now investigating whether the same effect will be seen in T1D. This study has been […]
Family members of people with T1D are at increased risk of developing the disease themselves. Type1Screen is a free screening service available to any family member of a person with T1D, that can find out a person’s risk of developing T1D. Those at increased risk will be offered the opportunity to enrol in trials of […]